Skip to content

Telemedicine for Reach, Education, Access and Treatment-ongoing

Telemedicine for Reach, Education, Access and Treatment-ongoing

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04107935
Acronym
TREAT-ON
Enrollment
43
Registered
2019-09-27
Start date
2020-02-04
Completion date
2022-12-09
Last updated
2023-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Keywords

Self management education and support, Telemedicine, Rural

Brief summary

Diabetes (DM) management requires health care providers to provide patients with the appropriate amount of time, education and support that are necessary for quality care. Unfortunately, this is often impeded by limited access to resources, particularly in rural communities where DM rates are high and providers are scarce. Therefore, study investigators propose addressing these issues by implementing a model of care that includes diabetes educator (DE)-led planned visits with a real-time videoconferencing telemedicine program for ongoing patient support to improve DM outcomes.

Detailed description

Health care systems need to seek ways through quality improvement, care coordination, and workforce capacity to support quality care. It has been proposed that new models of care coupled with technology are needed. DM provides an ideal model for testing new approaches as the number of people with DM continues to rise, with an inverse shortage of health providers available to meet their needs. Most patients with Type 2 DM (T2DM) are seen in primary care (PC) where providers report barriers to comprehensive care that include limited time, educational resources, added workload and feeling ill-equipped to counsel patients on behavior change. Efforts to restructure PC are underway, like DE-led planned management visits, reported to improve healthy behaviors and outcomes in patients at high risk. DEs are well suited to support the skills, decision making, self-care behaviors, problem solving and active collaboration with the care team that serve as the foundation for diabetes self-management education and key to an effective planned visit. DEs supporting care and self-management education in PC have been shown to improve access and outcomes. For patients to sustain a lifetime of behavior to effectively self-manage, continued support to sustain the ongoing skills, knowledge, and behaviors required to manage their condition is needed. Given the need for enduring support and scarcity of providers, particularly in underserved rural areas, efforts to understand how best to re-design practice to involve DEs in PC and utilize technology to enable and scale engagement in self-management and ongoing support must be considered. The purpose of this application is to evaluate the deployment of Telemedicine for Reach, Education, Access, Treatment and Ongoing Support (TREAT-ON), a DE-driven, PC-based telemedicine model that relies on PC practice redesign to afford access to real-time ongoing support. Investigators hypothesize that the TREAT-ON model will help individuals identified as being high risk in an underserved rural community to achieve and sustain improvements in clinical, psychosocial and behavioral outcomes, and aim to demonstrate the model's viability in terms of feasibility and acceptability to inform future testing of TREAT-ON.

Interventions

BEHAVIORALTREAT-ON

TREAT-ON is a DE-driven self-management and support program that is delivered primarily through a real-time telemedicine videoconferencing platform. Like the usual care intervention, high risk patients with DM receiving care in underserved practices will be identified by a nurse practice-based manager (PCBM) and referred to a DE for self management services. Participants will complete an initial face-to-face visit with the DE to assess needs and develop a self-management treatment plan and goals. Via telemedicine videoconferencing, follow-up visits will be delivered by the DE to participants in their homes. Follow-up visits will be used to evaluate and support progress towards meeting and sustaining self-management goals and outcomes.

BEHAVIORALUsual Care

A retrospective control group will be formed from individuals who have previously participated in a program called the Diabetes High Risk Initiative. In this program, patients receiving care in underserved practices are identified by a nurse PBCM to be at high risk for DM complications and/or unplanned care and referred to a DE for self management services delivered through primary care. Patients typically participate in one face-to-face visit with the DE to assess needs and develop self-management goals and then one to two follow-up encounters (generally conducted by telephone) with the PBCM or DE.

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
University of Pittsburgh
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Intervention group: UPMC Health Plan patient-members who are 18-75y, have diagnosis of type 2 diabetes, are considered high risk (HbA1c \>9%), receiving care at participating Federally Qualified Health Centers, and willing and able to participate in a technology-supported intervention. * Control group: The control group will be selected from individuals who have already participated in the UPMC Health Plan's Diabetes High Risk Initiative.

Exclusion criteria

* Non UPMC Health Plan patients * Not enrolled in the UPMC Health Plan Diabetes High Risk Initiative * Less than 18 or greater than 75 years of age * Unwilling/unable to participate in the telemedicine diabetes education program

Design outcomes

Primary

MeasureTime frameDescription
Change From Baseline in Glycemic ControlChange every 3 months for 12 months.Average change in HbA1c every 3 months from baseline through 12 months was assessed using mixed model regression with repeat measures and therefore there is only one result reported per arm.

Secondary

MeasureTime frameDescription
Change From Baseline in Diabetes Self-care Behavior [Diet] Across 3 Month Intervals for 12 Months.Change every 3 months for 12 months total.Summary of Diabetes Self-care Activities Measure was used to evaluate self-care with questions about number of days in a week that the participant reports self-care behaviors. Individual items are scored 0 (minimum) to 7 (maximum) for number of days the behavior is performed. The total possible score ranges from 0 to 7. The higher the score for dietary behavior, the better. For this study, average change in scores from baseline through 12 months was assessed using mixed model regression with repeat measures and therefore there is only one result reported per arm.
Change From Baseline in Diabetes Distress Across 3 Month Intervals for 12 MonthsChange every three months for 12 months totalDiabetes distress was evaluated with the 17-item Diabetes Distress Scale, which assesses four dimensions of distress - emotional, regimen, interpersonal and physician (Polonsky et al, 2005), and has shown a consistent pattern of relationships with HbA1c, diabetes self-efficacy, diet and physical activity in multiple samples of patients with T2DM (Fisher et al, 2012). Individual items are scored from 1 to 6; total scores are the average of all individual item scores; higher scores indicate greater distress (represents worse outcome). Possible score range 1 to 6. For this study, average change in scores every 3 months from baseline through 12 months was assessed using mixed model regression with repeat measures and therefore there is only 1 result reported per arm.
Change From Baseline in Diabetes Empowerment Across 3 Month Intervals for 12 MonthsChange every 3 months for 12 months totalEmpowerment was measured using the 8-item Diabetes Empowerment Scale-Short Form, which measures an individual's perceived ability to manage psychosocial aspects of diabetes, assess dissatisfaction and readiness to change self-management plans and set and achieve diabetes goals (Anderson et al, 2000; Anderson et al, 2003). Possible scores are 1 to 5 for each item, summed for a possible total score of 8 to 40. Higher scores indicate greater empowerment (better outcome). For this study, average change in scores every 3 months from baseline through 12 months was assessed using mixed model regression with repeat measures and therefore there is only 1 result reported per arm.
Intervention Acceptability12 monthsTelemedicine Usability Questionnaire was used to assess telehealth usefulness, ease of use and learnability, interface quality, patient-clinician interaction, reliability, satisfaction and future use and included additional items specific to this study. Individual items are scored on a scale from one to five, with one being strongly disagree to five being strongly agree. Scores are averaged for a possible score range of one to five. The higher the score infers the better the usability of the telehealth service.
Change From Baseline in Medication Adherence Across 3 Month Intervals for 12 MonthsChange every 3 months for 12 months totalMedication adherence was assessed with the 8-item Morisky Medication Adherence Scale (MMAS-8). The scales includes 8 items. Scores can range from 0 to 8; the higher the score, the more adherent the respondent is considered. For this study, average change in scores every 3 months from baseline through 12 months was assessed using mixed model regression with repeat measures and therefore there is only 1 result reported per arm.

Countries

United States

Participant flow

Recruitment details

Participants were recruited from federally qualified health centers that offered a diabetes program to high risk patients who met certain criteria.

Pre-assignment details

Usual care is a historical comparison group, therefore usual care participants were not considered to be enrolled into the study.

Participants by arm

ArmCount
Intervention
Intervention: TREAT-ON is a DE-driven self-management and support program that is delivered primarily through a real-time telemedicine videoconferencing platform. Like the usual care intervention, high risk patients with DM receiving care in underserved practices will be identified by a nurse practice-based manager (PCBM) and referred to a DE for self management services. Participants will complete an initial visit with the DE to assess needs and develop a self-management treatment plan and goals. Via telemedicine videoconferencing, follow-up visits will be delivered by the DE to participants in their homes. Follow-up visits will be used to evaluate and support progress towards meeting and sustaining self-management goals and outcomes.
43
Usual Care
Usual Care: A retrospective control group will be formed from individuals who have previously participated in a program called the Diabetes High Risk Initiative. In this program, patients receiving care in underserved practices are identified by a nurse PBCM to be at high risk for DM complications and/or unplanned care and referred to a DE for self management services delivered through primary care. Patients typically participate in face-to-face visit(s) with the DE to assess needs and develop self-management goals and then one to two follow-up encounters (generally conducted by telephone) with the PBCM or DE.
30
Total73

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyDeath10

Baseline characteristics

CharacteristicInterventionTotalUsual Care
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
2 Participants5 Participants3 Participants
Age, Categorical
Between 18 and 65 years
41 Participants68 Participants27 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants1 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
41 Participants71 Participants30 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants1 Participants0 Participants
Hemoglobin A1c10.8 % glycated hemoglobin10.6 % glycated hemoglobin10.4 % glycated hemoglobin
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
8 Participants13 Participants5 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
35 Participants60 Participants25 Participants
Region of Enrollment
United States
43 participants73 participants30 participants
Sex: Female, Male
Female
24 Participants43 Participants19 Participants
Sex: Female, Male
Male
19 Participants30 Participants11 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
1 / 430 / 30
other
Total, other adverse events
0 / 430 / 30
serious
Total, serious adverse events
0 / 430 / 30

Outcome results

Primary

Change From Baseline in Glycemic Control

Average change in HbA1c every 3 months from baseline through 12 months was assessed using mixed model regression with repeat measures and therefore there is only one result reported per arm.

Time frame: Change every 3 months for 12 months.

Population: Using propensity score matching, 30 intervention participants were paired with 30 usual care participants to compare changes in hemoglobin A1c.

ArmMeasureValue (MEAN)
InterventionChange From Baseline in Glycemic Control-0.14 % change
Usual CareChange From Baseline in Glycemic Control-0.14 % change
p-value: 0.983Mixed Models Analysis
Secondary

Change From Baseline in Diabetes Distress Across 3 Month Intervals for 12 Months

Diabetes distress was evaluated with the 17-item Diabetes Distress Scale, which assesses four dimensions of distress - emotional, regimen, interpersonal and physician (Polonsky et al, 2005), and has shown a consistent pattern of relationships with HbA1c, diabetes self-efficacy, diet and physical activity in multiple samples of patients with T2DM (Fisher et al, 2012). Individual items are scored from 1 to 6; total scores are the average of all individual item scores; higher scores indicate greater distress (represents worse outcome). Possible score range 1 to 6. For this study, average change in scores every 3 months from baseline through 12 months was assessed using mixed model regression with repeat measures and therefore there is only 1 result reported per arm.

Time frame: Change every three months for 12 months total

Population: Participants in the intervention group

ArmMeasureValue (MEAN)
InterventionChange From Baseline in Diabetes Distress Across 3 Month Intervals for 12 Months0.1693 Score on scale
Usual CareChange From Baseline in Diabetes Distress Across 3 Month Intervals for 12 Months-0.01655 Score on scale
p-value: 0.5727Mixed Models Analysis
Secondary

Change From Baseline in Diabetes Empowerment Across 3 Month Intervals for 12 Months

Empowerment was measured using the 8-item Diabetes Empowerment Scale-Short Form, which measures an individual's perceived ability to manage psychosocial aspects of diabetes, assess dissatisfaction and readiness to change self-management plans and set and achieve diabetes goals (Anderson et al, 2000; Anderson et al, 2003). Possible scores are 1 to 5 for each item, summed for a possible total score of 8 to 40. Higher scores indicate greater empowerment (better outcome). For this study, average change in scores every 3 months from baseline through 12 months was assessed using mixed model regression with repeat measures and therefore there is only 1 result reported per arm.

Time frame: Change every 3 months for 12 months total

Population: Participants in the intervention group

ArmMeasureValue (MEAN)
InterventionChange From Baseline in Diabetes Empowerment Across 3 Month Intervals for 12 Months0.01418 Score on a scale
Usual CareChange From Baseline in Diabetes Empowerment Across 3 Month Intervals for 12 Months0.01129 Score on a scale
p-value: 0.9381Mixed Models Analysis
Secondary

Change From Baseline in Diabetes Self-care Behavior [Diet] Across 3 Month Intervals for 12 Months.

Summary of Diabetes Self-care Activities Measure was used to evaluate self-care with questions about number of days in a week that the participant reports self-care behaviors. Individual items are scored 0 (minimum) to 7 (maximum) for number of days the behavior is performed. The total possible score ranges from 0 to 7. The higher the score for dietary behavior, the better. For this study, average change in scores from baseline through 12 months was assessed using mixed model regression with repeat measures and therefore there is only one result reported per arm.

Time frame: Change every 3 months for 12 months total.

Population: Intervention participants

ArmMeasureValue (MEAN)
InterventionChange From Baseline in Diabetes Self-care Behavior [Diet] Across 3 Month Intervals for 12 Months.0.08 Score on a scale
Usual CareChange From Baseline in Diabetes Self-care Behavior [Diet] Across 3 Month Intervals for 12 Months.0.09 Score on a scale
p-value: 0.8365Mixed Models Analysis
Secondary

Change From Baseline in Medication Adherence Across 3 Month Intervals for 12 Months

Medication adherence was assessed with the 8-item Morisky Medication Adherence Scale (MMAS-8). The scales includes 8 items. Scores can range from 0 to 8; the higher the score, the more adherent the respondent is considered. For this study, average change in scores every 3 months from baseline through 12 months was assessed using mixed model regression with repeat measures and therefore there is only 1 result reported per arm.

Time frame: Change every 3 months for 12 months total

Population: Participant in the intervention

ArmMeasureValue (MEAN)
InterventionChange From Baseline in Medication Adherence Across 3 Month Intervals for 12 Months0.1419 Score on a scale
Usual CareChange From Baseline in Medication Adherence Across 3 Month Intervals for 12 Months0.1044 Score on a scale
p-value: 0.608Mixed Models Analysis
Secondary

Intervention Acceptability

Telemedicine Usability Questionnaire was used to assess telehealth usefulness, ease of use and learnability, interface quality, patient-clinician interaction, reliability, satisfaction and future use and included additional items specific to this study. Individual items are scored on a scale from one to five, with one being strongly disagree to five being strongly agree. Scores are averaged for a possible score range of one to five. The higher the score infers the better the usability of the telehealth service.

Time frame: 12 months

Population: Participants in intervention group who completed the survey

ArmMeasureValue (MEAN)
InterventionIntervention Acceptability4.6 Score on a scale

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026